CITIUS PHARMACEUTICALS INC (CTXR) Fundamental Analysis & Valuation

NASDAQ:CTXR • US17322U3068

0.9622 USD
+0.09 (+10.6%)
At close: Mar 13, 2026
0.9358 USD
-0.03 (-2.74%)
After Hours: 3/13/2026, 4:30:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CTXR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, CTXR scores 2 out of 10 in our fundamental rating. CTXR was compared to 193 industry peers in the Pharmaceuticals industry. CTXR may be in some trouble as it scores bad on both profitability and health. CTXR has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

1

1. CTXR Profitability Analysis

1.1 Basic Checks

  • CTXR had negative earnings in the past year.
  • CTXR had a negative operating cash flow in the past year.
  • In the past 5 years CTXR always reported negative net income.
  • CTXR had a negative operating cash flow in each of the past 5 years.
CTXR Yearly Net Income VS EBIT VS OCF VS FCFCTXR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • CTXR's Return On Assets of -25.56% is in line compared to the rest of the industry. CTXR outperforms 57.51% of its industry peers.
  • CTXR has a Return On Equity (-44.88%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -25.56%
ROE -44.88%
ROIC N/A
ROA(3y)-31.85%
ROA(5y)-28.46%
ROE(3y)-49.95%
ROE(5y)-40.22%
ROIC(3y)N/A
ROIC(5y)N/A
CTXR Yearly ROA, ROE, ROICCTXR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40 -50

1.3 Margins

  • CTXR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTXR Yearly Profit, Operating, Gross MarginsCTXR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. CTXR Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CTXR has more shares outstanding
  • CTXR has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for CTXR is higher compared to a year ago.
CTXR Yearly Shares OutstandingCTXR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
CTXR Yearly Total Debt VS Total AssetsCTXR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

2.2 Solvency

  • Based on the Altman-Z score of -3.13, we must say that CTXR is in the distress zone and has some risk of bankruptcy.
  • CTXR has a Altman-Z score (-3.13) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.01 indicates that CTXR is not too dependend on debt financing.
  • CTXR's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. CTXR outperforms 56.99% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -3.13
ROIC/WACCN/A
WACCN/A
CTXR Yearly LT Debt VS Equity VS FCFCTXR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

2.3 Liquidity

  • CTXR has a Current Ratio of 0.99. This is a bad value and indicates that CTXR is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CTXR has a worse Current ratio (0.99) than 83.94% of its industry peers.
  • A Quick Ratio of 0.40 indicates that CTXR may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.40, CTXR is not doing good in the industry: 89.64% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.4
CTXR Yearly Current Assets VS Current LiabilitesCTXR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CTXR Growth Analysis

3.1 Past

  • CTXR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.99%, which is quite impressive.
EPS 1Y (TTM)29.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 22.32% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, CTXR will show a very strong growth in Revenue. The Revenue will grow by 112.22% on average per year.
EPS Next Y141.4%
EPS Next 2Y64.19%
EPS Next 3Y37.83%
EPS Next 5Y22.32%
Revenue Next Year731.6%
Revenue Next 2Y353.74%
Revenue Next 3Y213.93%
Revenue Next 5Y112.22%

3.3 Evolution

CTXR Yearly Revenue VS EstimatesCTXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
CTXR Yearly EPS VS EstimatesCTXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

4

4. CTXR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CTXR. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 0.34, the valuation of CTXR can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, CTXR is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
  • CTXR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.82.
Industry RankSector Rank
PE N/A
Fwd PE 0.34
CTXR Price Earnings VS Forward Price EarningsCTXR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTXR Per share dataCTXR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • CTXR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CTXR's earnings are expected to grow with 37.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y64.19%
EPS Next 3Y37.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CTXR Dividend Analysis

5.1 Amount

  • No dividends for CTXR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CTXR Fundamentals: All Metrics, Ratios and Statistics

CITIUS PHARMACEUTICALS INC

NASDAQ:CTXR (3/13/2026, 4:30:01 PM)

After market: 0.9358 -0.03 (-2.74%)

0.9622

+0.09 (+10.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12
Earnings (Next)05-12
Inst Owners7.66%
Inst Owner Change175.57%
Ins Owners2.2%
Ins Owner Change0%
Market Cap21.53M
Revenue(TTM)3.94M
Net Income(TTM)-35.89M
Analysts80
Price Target5.1 (430.04%)
Short Float %15.43%
Short Ratio3.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-44.04%
Min Revenue beat(2)-100%
Max Revenue beat(2)11.92%
Revenue beat(4)1
Avg Revenue beat(4)-72.02%
Min Revenue beat(4)-100%
Max Revenue beat(4)11.92%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-12.63%
EPS NY rev (3m)361.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.34
P/S 5.46
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.09
EYN/A
EPS(NY)2.85
Fwd EY295.76%
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-1.56
OCFYN/A
SpS0.18
BVpS3.57
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.56%
ROE -44.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.85%
ROA(5y)-28.46%
ROE(3y)-49.95%
ROE(5y)-40.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.99
Quick Ratio 0.4
Altman-Z -3.13
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.66%
EPS Next Y141.4%
EPS Next 2Y64.19%
EPS Next 3Y37.83%
EPS Next 5Y22.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year731.6%
Revenue Next 2Y353.74%
Revenue Next 3Y213.93%
Revenue Next 5Y112.22%
EBIT growth 1Y12.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.68%
OCF growth 3YN/A
OCF growth 5YN/A

CITIUS PHARMACEUTICALS INC / CTXR FAQ

What is the fundamental rating for CTXR stock?

ChartMill assigns a fundamental rating of 2 / 10 to CTXR.


What is the valuation status of CITIUS PHARMACEUTICALS INC (CTXR) stock?

ChartMill assigns a valuation rating of 4 / 10 to CITIUS PHARMACEUTICALS INC (CTXR). This can be considered as Fairly Valued.


How profitable is CITIUS PHARMACEUTICALS INC (CTXR) stock?

CITIUS PHARMACEUTICALS INC (CTXR) has a profitability rating of 1 / 10.


How financially healthy is CITIUS PHARMACEUTICALS INC?

The financial health rating of CITIUS PHARMACEUTICALS INC (CTXR) is 1 / 10.


What is the expected EPS growth for CITIUS PHARMACEUTICALS INC (CTXR) stock?

The Earnings per Share (EPS) of CITIUS PHARMACEUTICALS INC (CTXR) is expected to grow by 141.4% in the next year.